Literature DB >> 31450162

The lung microbiome dynamics between stability and exacerbation in chronic obstructive pulmonary disease (COPD): Current perspectives.

Efrosini Dima1, Anna Kyriakoudi1, Maria Kaponi1, Ioannis Vasileiadis1, Panagiota Stamou1, Antonia Koutsoukou1, Nikolaos G Koulouris1, Nikoletta Rovina2.   

Abstract

Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disorder with a course that is not uniform for all COPD patients. Although smoking is considered as the major cause of the disease, persistent or recurrent infections seem to play a particular role in the disease establishment and progression. COPD is characterized by dysregulated immunity that has been associated with the bacterial colonization and infections. The establishment of culture-independent techniques has shed new light on the relationships between bacterial ecology and health status and expanded our knowledge on the lung microbiome. Interactions between the host and lung microbiome result in inflammation and activation of resident cells. The lung microbiome contains populations of symbionts and pathobionts in balance which lose their equilibrium and disturb the balance of T-helper and regulatory T-cells (Treg) upon infection, or lung disease. In COPD factors such as disease severity, exacerbations, degree of inflammation, and type of treatment used (e.g inhaled or systemic steroids and antibiotics) affect the composition of lung microbiota. Recent data indicate that the presence of specific bacterial taxa in the airways has the potential to influence the host immune response and possibly to interfere with disease phenotype. Although, there is a growing body of evidence for the role of microbiome in COPD several unanswered questions still exist for its clinical relevance.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chronic obstructive pulmonary disease; Immune responses; Inflammation; Microbiome

Year:  2019        PMID: 31450162     DOI: 10.1016/j.rmed.2019.08.012

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  17 in total

Review 1.  Close Encounters of the Viral Kind: Cross-Kingdom Synergies at the Host-Pathogen Interface.

Authors:  Hannah M Rowe; Jason W Rosch
Journal:  Bioessays       Date:  2019-11-06       Impact factor: 4.345

2.  Risk factors and pathogenic microorganism characteristics for pneumonia in convalescent patients with stroke: A retrospective study of 380 patients from a rehabilitation hospital: A retrospective study of risk factors and pathogenic microorganism characteristics for pneumonia in convalescent patients with stroke.

Authors:  Jia Xu; Zhiling Yang
Journal:  J Stroke Cerebrovasc Dis       Date:  2020-05-14       Impact factor: 2.136

3.  Complex Evaluation of Surfactant Protein A and D as Biomarkers for the Severity of COPD.

Authors:  Mei-Yu Lv; Li-Xia Qiang; Bao-Cai Wang; Yue-Peng Zhang; Zhi-Heng Li; Xiang-Shun Li; Ling-Ling Jin; Shou-De Jin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-07-02

4.  Circulating 1,3-Beta-D-Glucan is Associated with Lung Function, Respiratory Symptoms, and Mediators of Matrix Degradation in Chronic Obstructive Pulmonary Disease.

Authors:  Matthew Gorgone; Deepti Singhvi; Seyed Mehdi Nouraie; Malcolm Finkelman; Yonglong Zhang; Jiantao Pu; Divay Chandra; Yingze Zhang; Georgios D Kitsios; Alison Morris; Frank C Sciurba; Jessica Bon
Journal:  Chronic Obstr Pulm Dis       Date:  2022-07-29

5.  Risk factors and pathogenic microorganism characteristics for pneumonia in convalescent patients with stroke: A retrospective study of 380 patients from a rehabilitation hospital.

Authors:  Jia Xu; Zhiling Yang
Journal:  J Stroke Cerebrovasc Dis       Date:  2020-05-14       Impact factor: 2.136

6.  Bacteria and sputum inflammatory cell counts; a COPD cohort analysis.

Authors:  Augusta S Beech; Simon Lea; Umme Kolsum; Zhang Wang; Bruce E Miller; Gavin C Donaldson; Jadwiga A Wedzicha; Christopher E Brightling; Dave Singh
Journal:  Respir Res       Date:  2020-11-01

7.  Metagenomic analysis of the lung microbiome in pulmonary tuberculosis - a pilot study.

Authors:  Yongfeng Hu; Min Cheng; Bo Liu; Jie Dong; Lilian Sun; Jian Yang; Fan Yang; Xinchun Chen; Qi Jin
Journal:  Emerg Microbes Infect       Date:  2020-12       Impact factor: 7.163

Review 8.  How might endotyping guide chronic obstructive pulmonary disease treatment? Current understanding, knowledge gaps and future research needs.

Authors:  Robert M Burkes; Ralph J Panos; Michael T Borchers
Journal:  Curr Opin Pulm Med       Date:  2021-03-01       Impact factor: 3.155

9.  Comparative analysis of the bronchoalveolar microbiome in Portuguese patients with different chronic lung disorders.

Authors:  Susana Seixas; Allison R Kolbe; Sílvia Gomes; Maria Sucena; Catarina Sousa; Luís Vaz Rodrigues; Gilberto Teixeira; Paula Pinto; Tiago Tavares de Abreu; Cristina Bárbara; Júlio Semedo; Leonor Mota; Ana Sofia Carvalho; Rune Matthiesen; Patrícia Isabel Marques; Marcos Pérez-Losada
Journal:  Sci Rep       Date:  2021-07-22       Impact factor: 4.379

Review 10.  Unmet needs in the management of exacerbations of chronic obstructive pulmonary disease.

Authors:  Kiki Waeijen-Smit; Sarah Houben-Wilke; Antonio DiGiandomenico; Ulf Gehrmann; Frits M E Franssen
Journal:  Intern Emerg Med       Date:  2021-02-22       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.